A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

Start Date13 Nov 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

NCT04379518

/ SuspendedPhase 1/2IIT

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.

Start Date17 Nov 2020

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

CTRI/2020/04/024498

/ Not yet recruitingPhase 2

COMPARATIVE EVALUATION OF TOPICAL CYCLOSPORINE A AND TOPICAL INTERFERON ALPHA 2B AS AN ADJUNCT TO LIMBAL CONJUNCTIVAL AUTOGRAFT IN PTERYGIUM SURGERY

Start Date15 Apr 2020

Sponsor / Collaborator-

100 Clinical Results associated with INTERFERON ALFA-2B(Merck Sharp & Dohme )

100 Translational Medicine associated with INTERFERON ALFA-2B(Merck Sharp & Dohme )

100 Patents (Medical) associated with INTERFERON ALFA-2B(Merck Sharp & Dohme )

2,087

Literatures (Medical) associated with INTERFERON ALFA-2B(Merck Sharp & Dohme )

01 Apr 2025·INDIAN JOURNAL OF OPHTHALMOLOGY

OSSN in South India: Clinical presentation, treatment outcomes, and histopathologic correlations

Article

Author: Bhaskaran, Sahithya ; Prasad, P V Tejaswi ; Prajna, N Venkatesh ; Radhakrishnan, Naveen ; Krishnan, Shanti Radha

Purpose::

This study aimed to analyze the clinical presentation, treatment outcomes, and histopathology features of ocular surface squamous neoplasia (OSSN) in a South Indian population and correlate the area of lesions to the histopathological grade/severity of carcinoma in situ (CIN) and squamous cell carcinoma (SqCC) invasive and noninvasive tumors.

Methods::

The study was a retrospective cross-sectional study. The study reviewed electronic medical records (EMRs) of 99 eyes of 99 South Indian patients who underwent en bloc excision and biopsy for tumors in the corneal and conjunctival epithelium with suspicion of OSSN over 1 year from January 2019 to December 2019. Postoperatively, patients were treated with three cycles of topical 0.04% mitomycin C eye drops. Sixty-three had requisite EMR data with a follow-up period of 1 year.

Results::

Patients had equal gender distribution with an age range of 28–83 years. The most common clinical variant was leukoplakic lesion, and the area of the lesion was the only predicting factor for SqCC and CIN.

Conclusion::

Bigger (T2) lesions should be strongly suspected for OSSN and promptly excised. Histopathologic analysis should be performed, and post-op topical mitomycin C or interferon alpha 2b is administered to avoid recurrence. In this study, by correlating the area of the lesion, we introduce a new variable that may aid in clinical prognostication alongside the AJCC classification.

01 Mar 2025·Actas urologicas espanolas

Adjuvant treatment in intermediate/high-risk clear cell renal cell carcinoma. Systematic review

Review

Author: Arrabal-Martín, M ; Millán-Ramos, I ; Gutiérrez-Tejero, F ; Arrabal-Polo, M Á ; Zambudio-Munuera, A ; Gómez-Morón, L

INTRODUCTION:

Given the lack of comparative studies on adjuvant treatment for clear cell renal cell carcinoma, we present an updated systematic review, exploring the various options for adjuvant therapy. This review is conducted in accordance with the PRISMA guidelines.

MATERIAL AND METHOD:

A systematic review was conducted, and 13 clinical trials were included after applying the pre-specified inclusion criteria. The risk of bias and the level of evidence were assessed. Subsequently, the requisite data were extracted in order to present the findings of the studies.

RESULTS AND DISCUSSION:

The present systematic review establishes that pembrolizumab can be used as adjuvant therapy in patients with advanced renal cancer at high risk after nephrectomy. This is supported by the KEYNOTE-564 study, which concluded that it increased disease-free survival (DFS) and overall survival (OS). The use of sunitinib is discussed, since the study published in NEJM shows a modest benefit in terms of DFS, but only in an independent and blinded central review. According to the PROTECT study, pazopanib has no overall benefit. The EVEREST study showed no significant benefit over everolimus. Further studies are needed to confirm the use of axitinib, as the ATLAS trial showed statistically significant results in DFS in higher-risk population based on investigator assessment, but not based on independent central review. Therapy with 5-FU, α-IFN and IL-2, atezolizumab, sorafenib, thalidomide, nivolumab + ipilimumab should not be used in the adjuvant setting.

01 Mar 2025·CURRENT OPINION IN UROLOGY

Contemporary nonsurgical management of Peyronie's disease

Review

Author: Tentis, Elise ; Pinkhasov, Alexandr M. ; Ziegelmann, Matthew ; Yang, David Y.

Purpose of review:

Peyronie's disease characterizes a condition in which there is angular curvature of the penis. We know that the most patients with Peyronie's disease will not have spontaneous resolution of their penile curvature. As such, patients who desire treatment can elect for either surgical or nonsurgical therapy. Herein, we discuss the contemporary nonsurgical management options for Peyronie's disease.

Recent findings:

Nonsurgical management options for Peyronie's disease include oral therapy, intra-lesional injections, and penile traction therapy. At the time of this review, there is essentially no high-level evidence demonstrating any benefit for oral therapy. Penile traction therapy has evolved over the past decade with second-generation devices demonstrating strong efficacy and more convenient treatment regimens. Intra-lesional options include collagenase Clostridium histolyticum (CCH), verapamil, and interferon alpha-2b. The IMPRESS trial garnered the strongest level of evidence (two randomized, double-blind, placebo-controlled trials) to support the safety and efficacy of CCH. Verapamil is an option supported by several urological societies; however, the evidence supporting its efficacy is inconsistent between several notable series and randomized studies. IFN alpha 2b can produce modest improvement in curvature, however, is not available for use in North America.

Summary:

Herein, we will discuss notable advances in nonsurgical management of Peyronie's disease.

News (Medical) associated with INTERFERON ALFA-2B(Merck Sharp & Dohme )

09 Sep 2024

·www.globenewswire.com

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors. The CX-801 Phase 1 dose escalation study is designed to evaluate safety and signs of clinical activity for CX-801 as monotherapy and in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab). In dose escalation, the Phase 1 study will enroll patients with select solid tumors including advanced melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma to inform a potential decision to move into Phase 1b indication-specific dose expansion cohorts. “Interferon-alpha-2b is a powerful immune-modulating cytokine that has demonstrated clinical activity in multiple cancer types such as metastatic melanoma, renal cancer and bladder cancer but its clinical benefit has been limited by significant toxicities when administered systemically. CX-801 utilizes CytomX’s industry leading conditional activation platform to maintain potency and expand interferon’s therapeutic index to potentially become a foundational component of immuno-oncology combination regimens,” said Wayne Chu, M.D., chief medical officer of CytomX Therapeutics. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA About CytomX Therapeutics. CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter). CytomX Therapeutics Forward-Looking StatementsThis press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements, including those related to the future potential of partnerships or collaboration agreements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product candidates, including CX-801, CX-904, and CX-2051, the potential benefits or applications of CytomX’s PROBODY® therapeutic platform, CytomX’s or its collaborative partners’ ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of CX-801, and the timing of initial and ongoing data availability for CX-801, and other development milestones. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel PROBODY® therapeutic technology; CytomX’s clinical trial product candidates are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the possibility that the results of preclinical research and early clinical trials, including initial CX-904 results, may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX’s dependence on the success of CX-904 CX-2051 and CX-801; CytomX’s reliance on third parties for the manufacture of the Company’s product candidates; possible regulatory developments in the United States and foreign countries; and the risk that we may incur higher costs than expected for research and development or unexpected costs and expenses. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise. PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc. Company Contact:Chris OgdenChief Financial Officercogden@cytomx.com Investor Contact:Precision AQ (formerly Stern Investor Relations)Stephanie Ascherstephanie.ascher@precisionaq.com Media Contact:Redhouse CommunicationsTeri Dahlmanteri@redhousecomms.com

Phase 1ImmunotherapyADC

12 Jun 2023

·www.globenewswire.com

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the treatment of pancreatic cancer (AMP-270) Ongoing progress toward Phase 1 data in clinical development program of Ampligen for the treatment of early-stage triple negative breast cancer Significant findings from a new analysis support the potential to identify patients with LAPC that could respond better to Ampligen Company bolsters patent portfolio for Ampligen as a potential therapy against Ebola virus disease OCALA, Fla., June 12, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today provided an update on its ongoing clinical development programs evaluating Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immune-modulator with broad spectrum activity. AIM Chief Executive Officer Thomas K. Equels commented, “We have made promising progress across multiple clinical fronts, and I am proud of the dedication of our team and their evident operational execution. Ampligen continues to demonstrate significant potential across multiple types of cancers, immune disorders and viral diseases. We are committed to advancing Ampligen’s development and are poised to achieve multiple key milestones in 2023.” Ampligen Phase 2 Study as a Therapy for Locally Advanced Pancreatic Cancer ("LAPC”) (AMP-270) The AMP-270 clinical trial is the Company’s randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Secondary objectives include comparing safety and tolerability. AMP-270 is expected to enroll approximately 90 subjects in up to 30 centers across the United States and Europe. The Company is recruiting patients for its AMP-270 Phase 2 study of Ampligen as a therapy for LAPC. The lead site at the University of Nebraska Medical Center is now open and actively working to enroll patients. The Gabrail Cancer & Research Center in Canton, Ohio is also recruiting patients. Kelsey Klute, MD, Medical Director of the Pancreatic Diseases Specialty Clinic at Nebraska Medicine, commented, “We are pleased to join into what we believe is an important Phase 2 study that has the potential to address a much-needed treatment option for LAPC. Our team is actively working to enroll and treat patients on the study in a joint effort with all other clinical trial sites. We are encouraged by the potential of Ampligen and look forward to further exploring its potential in the treatment of LAPC.” AIM continues its efforts to open additional clinical sites at premier cancer centers across the United States and Europe. The Company remains optimistic for first patient enrollment in the second quarter of this year. For more information about the AMP-270 please visit ClinicalTrials.gov and reference identifier NCT05494697. Ampligen Phase 1 Study for the Treatment of Early-Stage Triple Negative Breast Cancer (“TNBC”) Ampligen is currently being evaluated in a Phase 1 study for TNBC by Roswell Park Comprehensive Cancer Center. The study is designed to evaluate the safety and tolerability of a combination of Ampligen and celecoxib with or without Intron A, when given along with chemotherapy. The primary endpoint was safety and tolerability. Secondary endpoints included pCR rate. Tumor and blood biomarkers were analyzed in exploratory studies. The goal of this approach is to increase survival. In November 2022, Roswell presented positive data at the SITC 37th Annual Meeting demonstrating the chemokine-modulating regimen including Ampligen was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic). Roswell has now completed the study and is currently analyzing data. Based on current timelines, the Company anticipates Roswell will release — via publications — full study results before the end of the year. For more information about the Phase 1 study of Ampligen for the treatment of TNBC, visit ClinicalTrials.gov and reference identified NCT04081389. Ampligen Analysis Demonstrating Potential as a Maintenance Therapy After Systemic Chemotherapy in Patients with Metastatic and LAPC A new analysis was recently presented in an abstract titled, “Immune Response in Stable Pancreatic Cancer after Rintatolimod Treatment,” by Professor C.H.J. van Eijck, MD, PhD of Erasmus Medical Center at the 2023 Annual Pancreas Club Meeting held in Chicago, Illinois. Findings from the analysis demonstrated that treatment of patients with LAPC after FOLFIRINOX with Ampligen (rintatolimod) may induce markers of dendritic cells and T cells in a subgroup of patients. The absence of these markers may predict tumor progression after FOLFIRINOX, providing the future possibility of identifying pancreatic cancer patients who could potentially respond to Ampligen. The results from the new analysis build on the previously reported peer-reviewed article “Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program,” published in March 2022 in the journal Cancers. Ampligen as a Potential Therapy Against Ebola Virus Disease (“EVD”) The South African Patent and Trademark Office (CIPC) has granted patent No. 2022/01079, titled “Compositions and Methods Useful for Ebola Virus Infection.” This pioneering patent recognizes the efficacy of AIM’s tdsRNA drug family, of which Ampligen is a member, as a potential solution to combat the devastating impact of Ebola outbreaks. Under the newly granted patent, a composition comprising tdsRNA may be used in a method that involves administering the composition to a subject to prevent, treat, inhibit, or attenuate an Ebola virus infection in that subject. Significantly, the composition may be used as a treatment for individuals already infected with the Ebola virus, or the composition may be used to prevent an Ebola infection. About Ampligen Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors. Additionally, Ampligen has shown success in increasing survival rates and efficacy in the treatment of animal tumors when used in combination with checkpoint blockade therapies. Ampligen is currently being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country. Ampligen is being used to treat pancreatic cancer patients in an Early Access Program approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center. Additionally, Ampligen is also approved in Argentina for the treatment of severe chronic fatigue syndrome and is currently being evaluated in SARS-CoV-2/COVID-19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID Conditions. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Phase 1Phase 2ImmunotherapyASCOClinical Result

12 Apr 2023

·www.drugs.com

Interferon Alfa-2b Effective for Low-Grade Lymphomatoid Granulomatosis

WEDNESDAY, April 12, 2023 -- For low-grade lymphomatoid granulomatosis, interferon alfa-2b is efficacious, according to a study published online March 31 in The Lancet Haematology . Christopher Melani, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues enrolled 67 patients aged 12 years or older with untreated, relapsed, or refractory lymphomatoid granulomatosis. Patients with low-grade disease received dose-escalated interferon alfa-2b, and those with high-grade disease received six cycles of intravenous, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). After initial therapy, patients with residual or progressive disease crossed over to alternative therapy. Forty-five patients received initial treatment with interferon alfa-2b (16 crossed over to DA-EPOCH-R) and 18 received initial treatment with DA-EPOCH-R (eight crossed over to interferon alfa-2b); four only received surveillance. The researchers found that the overall response was 64 percent after initial treatment with interferon-alfa-2b (61 percent had complete response), while the overall response was 63 percent (50 percent with complete response) after cross-over treatment with interferon alfa-2b. The overall response rate was 76 percent after initial treatment with DA-EPOCH-R (47 percent had complete response), while the overall response was 67 percent (47 percent with complete response) after cross-over treatment with DA-EPOCH-R. Five-year progression-free survival was 48.5, 50.0, 25.4, and 62.5 percent, respectively, with initial treatment with interferon alfa-2b, cross-over treatment with interferon alfa-2b, initial treatment with DA-EPOCH-R, and cross-over treatment with DA-EPOCH-R, respectively. "We have shown in this rare disorder that using a novel immunotherapy-based approach for low-grade disease is effective and improves survival compared with historical treatments such as chemotherapy and corticosteroids," Melani said in a statement. One author disclosed financial ties to the biopharmaceutical industry. Abstract/Full Text (subscription or payment may be required) Editorial (subscription or payment may be required) Posted April 2023

Clinical ResultImmunotherapyPhase 3Clinical Study

100 Deals associated with INTERFERON ALFA-2B(Merck Sharp & Dohme )

External Link

KEGG	Wiki	ATC	Drug Bank
D02745	INTERFERON ALFA-2B(Merck Sharp & Dohme )	L03AB05	DB00105

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Carcinoid Tumor	European Union	Merck Sharp & Dohme BV	09 Mar 2000
Carcinoid Tumor	Iceland	Merck Sharp & Dohme BV	09 Mar 2000
Carcinoid Tumor	Liechtenstein	Merck Sharp & Dohme BV	09 Mar 2000
Carcinoid Tumor	Norway	Merck Sharp & Dohme BV	09 Mar 2000
Multiple Myeloma	European Union	Merck Sharp & Dohme BV	09 Mar 2000
Multiple Myeloma	Iceland	Merck Sharp & Dohme BV	09 Mar 2000
Multiple Myeloma	Liechtenstein	Merck Sharp & Dohme BV	09 Mar 2000
Multiple Myeloma	Norway	Merck Sharp & Dohme BV	09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia	European Union	Merck Sharp & Dohme BV	09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia	Iceland	Merck Sharp & Dohme BV	09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia	Liechtenstein	Merck Sharp & Dohme BV	09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia	Norway	Merck Sharp & Dohme BV	09 Mar 2000
Hepatitis C	China	Schering-Plough Corp.	27 Oct 1999
Kaposi Sarcoma	China	Schering-Plough Corp.	27 Oct 1999
AIDS-related Kaposi Sarcoma	United States	Merck Sharp & Dohme LLC	04 Jun 1986
Condylomata Acuminata	United States	Merck Sharp & Dohme LLC	04 Jun 1986
Follicular Lymphoma	United States	Merck Sharp & Dohme LLC	04 Jun 1986
Hairy Cell Leukemia	United States	Merck Sharp & Dohme LLC	04 Jun 1986
Hepatitis B, Chronic	United States	Merck Sharp & Dohme LLC	04 Jun 1986
Hepatitis C, Chronic	United States	Merck Sharp & Dohme LLC	04 Jun 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	France	Schering-Plough Corp.	01 Dec 2001
Melanoma, Cutaneous Malignant	Phase 3	-	Merck Sharp & Dohme LLC	05 Aug 1998
Hutchinson's Melanotic Freckle	Phase 1	United States	Merck Sharp & Dohme Corp.	10 Mar 2009
Acquired Immunodeficiency Syndrome	Phase 1	United States	Schering-Plough Corp.	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


APAO2024	Not Applicable	Malignant melanoma of conjunctiva Adjuvant	-	Interferon alpha-2b (IFN-α2b) eye drops	ysuninehju(doehyawofk) = gghqgewqua pwaarjxfba (nrnecdpbzu ) View more	Positive	22 Feb 2024
APAO2024	Not Applicable	Malignant melanoma of conjunctiva Adjuvant	-	Mitomycin C (MMC) eye drops	ysuninehju(doehyawofk) = gkjvxqnavf pwaarjxfba (nrnecdpbzu ) View more	Positive	22 Feb 2024
APAO2023	Not Applicable	Neoplasms	-	Recombinant Interferon alpha 2b (IFNÎ±2b) 3 million international units (IU) in 0.5 mL	zetjvrkutz(usdoscwukl) = post- injection flu like illness for 2 days uuprzkppia (nqepiujnsv )	-	23 Feb 2023
NCT03403634 (CTgov)	Phase 2	Liver metastases \| Colorectal cancer recurrent \| Colorectal Cancer	19	Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib	tndqdwofzq(jbtozhdrsf) = wmdalrtauo stohxotmxf (vxurvgewin, 13.79) View more	-	02 Mar 2022
NCT03552549 (MK-4031-002 \| C98-135, CTgov)	Phase 2/3	Melanoma, Cutaneous Malignant \| Melanoma	126	PEG-Intron (PEG-Intron)	vsoogzuqoo(buoewzpryt) = sflzzthdyh kbtkxzxvpb (oigyiecqxh, jpnjpqbgco - ghdpyhmnjs) View more	-	24 Jul 2019
NCT03552549 (MK-4031-002 \| C98-135, CTgov)	Phase 2/3	Melanoma, Cutaneous Malignant \| Melanoma	126	Intron A (INTRON A)	vsoogzuqoo(buoewzpryt) = wsbmjziitz kbtkxzxvpb (oigyiecqxh, ueynosqnkh - imoniuqivo) View more	-	24 Jul 2019
NCT01460875 (CTgov)	Not Applicable	Melanoma, Cutaneous Malignant	34	laboratory biomarker analysis+Intron A+Heberon Alfa	muxiiyzqlb(tiuysgikhm) = lypwvzhtbd acsspjsduq (nvsnaouuim, zftufkzsva - kzlkklyuoe) View more	-	02 Nov 2018
NCT01100528 (CTgov)	Phase 2	Uveal Melanoma	38	Recombinant Interferon Alfa-2b+Dacarbazine	gssfsactyj = jznqxwabmt cqmlzwfnmf (kyphnyatfh, ldsrqygpmk - qqiluxwjwx) View more	-	29 Oct 2018
2018 ARVO Annual Meeting (ARVO2018)	Not Applicable	Neoplasms Adjuvant	39	Topical interferon alpha-2b	dvggcxwmgx(idjrdanljv) = dszdqxodjy jylhwmufgw (glwbcxioal ) View more	Positive	01 Jul 2018
2018 ARVO Annual Meeting (ARVO2018)	Not Applicable	Neoplasms Adjuvant	39	Subconjunctival interferon alpha-2b	dvggcxwmgx(idjrdanljv) = zroitdozpp jylhwmufgw (glwbcxioal ) View more	Positive	01 Jul 2018
NCT02339324 (ASCO_SITC 12018 \| ASCO_SITC 22018) Manual	Phase 1	Neoadjuvant	30	pembrolizumab+IFN-α2b	lbgaajozel(fjlnpevnuv) = 4 events (↑CPK, hyperglycemia, lymphocyte count decreased) nccvfxzoye (qzolvficbe ) View more	Positive	25 Jan 2018
NCT01622933 (P138, SITC2017)	Phase 1	Melanoma HLA-A2 + \| CTLA-4 + \| TIM3 + ... View more	35	AdVTMM2 DC vaccine	kytptxtgkt(tfzxpwtaif) = Patients previously treated with α-CTLA-4 with/without α-PD-1 therapy had more tumor-specific IFN- γ-producing T cells before and after vaccination compared to patients that received no prior checkpoint blockade flodebbkhy (tnjyybazvw ) View more	Positive	07 Nov 2017
NCT00580372 (TT1, TT2, TT3a, TT3b, CTgov)	Phase 2	Multiple Myeloma	231	Autologous Hemopoietic Stem Cell Transplant 1+etoposide+Maintenance+High-Dose cyclophosphamide+cisplatin+VAD+dexamethasone+cytarabine	jlcvydaeua = phhroilugk xqumlkyezd (qrcoogtwtd, ojntvqcizu - xkurwoboef) View more	-	20 Sep 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis